Tiers name what a vendor publishes, not a verdict on any product's purity or quality.
Lab-verifiable COAs: certificates that open on the testing lab's own site (the seal's ring shows what share of them do).
Third-party COAs: certificates attributed to a third-party lab, which may be hosted only on the vendor's site.
Tiers follow the Vendor Score (90+ and 80–89), which is 87% COA evidence; the numeral in each seal is that score.
Affiliate relationships never affect tiers, selection or order. How the Vendor Score works
An investigational ActRIIB-Fc fusion protein studied as an inhibitor of myostatin and related ligands.
Evidence brief
ACE-031 is a soluble activin type-IIB receptor fused to an IgG1 Fc domain; it binds myostatin and other ligands involved in regulation of muscle mass.
Compare by exact vialThe small sealed glass container a compound ships in.The small sealed glass container a compound ships in. size:
1mg (6 vendors)
Your comparison
Selections stay on this browser. Prices and stock come from the current page; review freshness and COA notes for each offer. Scroll sideways to see every offer.
Select up to four offers to compare side by side. Click a column heading to sort. Click again to reverse. Scroll sideways for more columns.
Tick up to four offers to compare side by side. Use Sort by to reorder. COA counts are each vendor's own library; batch match is not assumed.
ACE-031 ramatercept · all tracked vendors · all tracked peptide listings, including out-of-stock products. Prices and stock reflect the last check. Non-comparable products do not enter market rankings. Trust scores measure published evidence, not product safety.
Checked within 24 hoursPrice and stock were collected in the latest refresh.just now
View product ↗Affiliate link: pepmg may earn a commission. Affiliate status never affects ranking, price order or Vendor Scores.
No matches. Try another search or reset the filters.
COACertificate of Analysis: a lab report stating a batch's measured identity and purity.Certificate of Analysis: a lab report stating a batch's measured identity and purity. availability: 7 of 7 tracked sources for ACE-031 ramatercept publish a COA
— 5 with at least one certificate you can open at the testing lab : RUO.bio (91 at the lab) , Nationwide Peptides (88 at the lab) , NuScience Peptides (87 at the lab) , Tegridy Research (81 at the lab) , Swiss Chems (72 at the lab) , Biotech Peptides , Core Peptides . What a COA proves →
● Research articles about ACE-031 ramaterceptAll research →
Source-linked reference figures with the population and study context alongside each amount. Study arms are not a starting dose, titration schedule, or personal treatment plan. Label records refer to the named approved medicine, not vendor products.
Dose administered in a randomised double-blind placebo-controlled single ascending-dose trial (human, 48 healthy postmenopausal women, ascending single-dose cohorts)
0.02 mg/kg to 3 mg/kg as a single dose
human · 48 healthy postmenopausal women, ascending single-dose cohorts · randomised double-blind placebo-controlled single ascending-dose trial · Route reported: subcutaneous
published per unit of bodyweight — pepmg reports it as published and does not convert it to an absolute amount
Trial registry (not peer-reviewed): dose registered for a clinical trial (NCT01099761, phase 2, terminated) (human, ambulant boys aged 4 years and older with Duchenne muscular dystrophy on stable corticosteroids (24 enrolled across two ACE-031 arms and placebo))
0.5 mg/kg once every 4 weeks for 12 weeks
human · ambulant boys aged 4 years and older with Duchenne muscular dystrophy on stable corticosteroids (24 enrolled across two ACE-031 arms and placebo) · registered phase 2 multiple ascending-dose trial, terminated based on safety data · Route reported: subcutaneous
published per unit of bodyweight — pepmg reports it as published and does not convert it to an absolute amount
Trial registry (not peer-reviewed): dose registered for a clinical trial (NCT01099761, phase 2, terminated) (human, ambulant boys aged 4 years and older with Duchenne muscular dystrophy on stable corticosteroids (24 enrolled across two ACE-031 arms and placebo))
1.0 mg/kg once every 2 weeks for 12 weeks
human · ambulant boys aged 4 years and older with Duchenne muscular dystrophy on stable corticosteroids (24 enrolled across two ACE-031 arms and placebo) · registered phase 2 multiple ascending-dose trial, terminated based on safety data · Route reported: subcutaneous
published per unit of bodyweight — pepmg reports it as published and does not convert it to an absolute amount
Research use only — this reports what an FDA label, a peer-reviewed study or a clinical-trial registry entry published, tied to its species and study context. A trial-registry figure is what a sponsor registered, not a peer-reviewed result. It is not medical advice, not a recommendation to use, and no dose here is generated by pepmg. Any dosing decision is for a qualified professional. Animal-study amounts do not establish a human dose.
ACE-031 is a soluble form of activin receptor type IIB (ActRIIB). ACE-031 promotes muscle growth by binding to myostatin and other negative regulators of muscle mass.
This double-blind, placebo-controlled study evaluated the safety,…
ACE-031 is a fusion protein of activin receptor type IIB and IgG1-Fc, which binds myostatin and related ligands. It aims to disrupt the inhibitory effect on muscle development and provide potential therapy for myopathies like Duchenne…
Studyhuman Drug testing and analysis · 2025 · PMID 40312924
The usage of ACE-031 (Ramatercept), a dimeric fusion protein consisting of a human activin receptor IIB (ACVR2B) fragment linked to an Fc-part of human IgG1, is banned according to chapter S4.3 of the "WADA 2024 List of Prohibited…
A few representative studies, each summarized on this site with the PubMed record linked beside it — not an endorsement or a claim that any result applies to human use. Read them and judge for yourself. Everything here is research use only.
All products listed are sold by third-party vendors for laboratory and research use only (RUO). Where an FDA label, a peer-reviewed study or a clinical-trial registry entry has published a dose, pepmg reports it with the source named and the tier labeled (a registry figure is marked trial registry, not peer-reviewed), because that is safer than guessing. It is a report, not medical advice and not a recommendation to use anything. pepmg sells nothing and ships nothing. Listings are price-tracking data, not endorsements.
✓
＋ Get the free Weekly Price Index One email a week — where every compound's $/mg moved. No spam.
